Outcomes of Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors with and Without Lung and/or Liver Metastases (NCI/SWOG S1609).
Rare cancer patients with both lung and liver tumors tend to do worse with dual immune therapy, informing treatment planning.
Limited prior retrospective data, primarily among patients with lung cancer, liver cancer, and melanoma, has indicated that liver metastases are associated with poorer outcomes with chemotherapy, targeted agents, and checkpoint inhibitor therapy. In a diverse cohort of participants with advanced rare tumors treated with combination anti-CTLA-4 and anti-PD-1 therapy, we found that both the combination of lung and liver metastases was associated with shorter PFS and OS.
What the study was
- Study design
- Retrospective observational study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of immunotherapy and precision oncology
Why it surfaced
⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Novel therapeutics: immunotherapy, CAR-T, targeted therapy; Design: Retrospective observational study; species: human
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.